These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28917156)

  • 1. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
    Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
    Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
    Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
    Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
    Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
    Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
    Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
    Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Schneider P; de Lorenzo P; Valsecchi MG; den Boer ML; Pieters R
    Blood; 2007 Oct; 110(7):2774-5. PubMed ID: 17881645
    [No Abstract]   [Full Text] [Related]  

  • 6. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
    Brown P; Levis M; McIntyre E; Griesemer M; Small D
    Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Schneider P; Meier M; Beverloo HB; Pieters R
    Haematologica; 2007 Nov; 92(11):1565-8. PubMed ID: 18024407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA; Schneider P; Hulleman E; de Boer J; Williams O; Pieters R; Stam RW
    Leukemia; 2012 Jun; 26(6):1255-65. PubMed ID: 22282267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
    Nasilowska-Adamska B; Solarska I; Paluszewska M; Malinowska I; Jedrzejczak WW; Warzocha K
    Ann Hematol; 2014 Apr; 93(4):577-93. PubMed ID: 24030729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Schneider P; Nollau P; Horstmann M; Beverloo HB; van der Voort E; Valsecchi MG; de Lorenzo P; Sallan SE; Armstrong SA; Pieters R
    Blood; 2005 Oct; 106(7):2484-90. PubMed ID: 15956279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
    Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y
    Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
    EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.
    Chillón MC; Gómez-Casares MT; López-Jorge CE; Rodriguez-Medina C; Molines A; Sarasquete ME; Alcoceba M; Miguel JD; Bueno C; Montes R; Ramos F; Rodríguez JN; Giraldo P; Ramírez M; García-Delgado R; Fuster JL; González-Díaz M; Menendez P
    Leukemia; 2012 Nov; 26(11):2360-6. PubMed ID: 22705992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.
    Català A; Pastor-Anglada M; Caviedes-Cárdenas L; Malatesta R; Rives S; Vega-García N; Camós M; Fernández-Calotti P
    Oncotarget; 2016 Aug; 7(31):49786-49799. PubMed ID: 27391351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapsed infant MLL-rearranged acute lymphoblastic leukemia with additional genetic alterations.
    Ishida H; Kanamitsu K; Washio K; Muraoka M; Sakakibara K; Matsubara T; Kanzaki H; Shimada A
    Pediatr Blood Cancer; 2016 Nov; 63(11):2059-60. PubMed ID: 27322816
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
    Albouhair S; Morgado E; Lavau C
    PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.